Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 2Neoplasm Metastasis 2Hemangiosarcoma 2Gastrointestinal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma, Endometrial Stromal 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Oligodendroglioma 1Gliosarcoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma 1Brain Neoplasms 1Advanced Hepatocellular Carcinoma 1

Interventions

trebananib 1pembrolizumab 1cabozantinib 1Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Hepatocellular Carcinoma × trebananib × Clear all
NCT00872014 2016-04-04

A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer

Amgen

Phase 2 Completed
60 enrolled
Gastrointestinal

Advanced Hepatocellular Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡